Pharmaceuticals Analysts discusses Hypothalamic Obesity Grand Rounds Ahead of Rhythm’s Phase 3 Data (RYTM) on an Analyst/Industry conference call to be held on March 24.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $66 from $64 at Needham
- Rhythm Pharmaceuticals, Raymond A. Wood Fountain announce research collab
- Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Positive Setmelanotide Trial Expectations
- Buy Rating for Rhythm Pharmaceuticals Driven by Promising Phase 3 Trial Results and Market Opportunity for Setmelanotide
- Rhythm Pharmaceuticals assumed with an Overweight at Morgan Stanley